Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031148 · ClinicalTrials.gov registry record · Phase 1
Keratinocyte Growth Factor to Prevent Acute GVHD
A Phase 1 study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00031148 is a Phase 1 study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 72 participants.
The verdict
NCT00031148, a Phase 1 study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.
Interventions
- DRUG Recombinant Human Keratinocyte Growth Factor (rHuKGF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031148
The ClinicalTrials.gov registry entry for NCT00031148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Keratinocyte Growth Factor (rHuKGF) is the first listed.
NCT00031148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031148 about?
NCT00031148 is a clinical study titled "Keratinocyte Growth Factor to Prevent Acute GVHD". This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.
What is the current status of trial NCT00031148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2001-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00031148?
The interventions under investigation include: Recombinant Human Keratinocyte Growth Factor (rHuKGF) (DRUG).
Who is sponsoring clinical trial NCT00031148?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.